Home LiteratureArticle Details
PMID: 17388672 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Why is long-term therapy required to cure tuberculosis?

PLoS medicine ·Vol. 4 ·No. 3 ·2007-03-00 ·Pages e120

Connolly LE, Edelstein PH, Ramakrishnan L

Abstract

暂无摘要

MeSH Terms
Antitubercular Agents/therapeutic use Drug Resistance, Bacterial/genetics Humans Mycobacterium tuberculosis/drug effects,genetics Tuberculosis, Multidrug-Resistant/drug therapy Tuberculosis, Pulmonary/drug therapy,microbiology
Chemicals
Antitubercular Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Connolly Lynn E
Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Edelstein Paul H
Ramakrishnan Lalita
References (93)
93 references, click to expand
  1. Bacterial persistence as a phenotypic switch.
    Science. 2004 Sep 10;305(5690):1622-5 PMID: 15308767
  2. Short-term treatment of uncomplicated lower urinary tract infections in women.
    Rev Infect Dis. 1990 May-Jun;12(3):458-67 PMID: 2193352
  3. Counts of viable tubercle bacilli in sputum related to smear and culture gradings.
    Med Lab Sci. 1992 Jun;49(2):94-8 PMID: 1487984
  4. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.
    Tuberculosis (Edinb). 2004;84(3-4):218-27 PMID: 15207491
  5. The PIN-domain toxin-antitoxin array in mycobacteria.
    Trends Microbiol. 2005 Aug;13(8):360-5 PMID: 15993073
  6. Distribution and excretion of radioactive isoniazid in tuberculous patients.
    J Am Med Assoc. 1953 Apr 18;151(16):1384-8 PMID: 13034481
  7. Staphylococcus aureus bacteremia. Current clinical patterns.
    Am J Med. 1976 Apr;60(4):495-500 PMID: 1274983
  8. The diagnosis and therapy of tuberculosis during the past 100 years.
    Am J Respir Crit Care Med. 2005 Apr 1;171(7):699-706 PMID: 15709048
  9. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial.
    Ann Intern Med. 1996 Dec 15;125(12):969-74 PMID: 8967707
  10. STREPTOMYCIN treatment of pulmonary tuberculosis.
    Br Med J. 1948 Oct 30;2(4582):769-82 PMID: 18890300
  11. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2005 Feb;49(2):627-31 PMID: 15673743
  12. Bacterial biofilms: a common cause of persistent infections.
    Science. 1999 May 21;284(5418):1318-22 PMID: 10334980
  13. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.
    N Engl J Med. 1995 Mar 23;332(12):779-84 PMID: 7862181
  14. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy.
    J Bacteriol. 2002 Dec;184(24):6760-7 PMID: 12446625
  15. Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo.
    Am Rev Tuberc. 1956 Nov;74(5):683-98 PMID: 13372954
  16. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.
    Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7534-9 PMID: 11416222
  17. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice.
    Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10026-31 PMID: 12897239
  18. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.
    Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79 PMID: 10529902
  19. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1996 Oct;40(10):2296-9 PMID: 8891133
  20. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts.
    Br J Exp Pathol. 1961 Feb;42:83-8 PMID: 13740304
  21. VIRULENCE AND MORPHOLOGICAL CHARACTERISTICS OF MAMMALIAN TUBERCLE BACILLI.
    J Exp Med. 1947 Jul 31;86(2):175-84 PMID: 19871665
  22. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection.
    Lancet. 2000 Dec 23-30;356(9248):2133-8 PMID: 11191539
  23. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.
    Am Rev Respir Dis. 1979 May;119(5):827-30 PMID: 453704
  24. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
    Am Rev Respir Dis. 1984 Dec;130(6):1091-4 PMID: 6508006
  25. Persisters: a distinct physiological state of E. coli.
    BMC Microbiol. 2006;6:53 PMID: 16768798
  26. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients.
    Tuber Lung Dis. 1996 Jun;77(3):244-9 PMID: 8758108
  27. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.
    Antimicrob Agents Chemother. 2006 Aug;50(8):2853-6 PMID: 16870785
  28. Persister cells and the riddle of biofilm survival.
    Biochemistry (Mosc). 2005 Feb;70(2):267-74 PMID: 15807669
  29. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality.
    Science. 2004 Sep 10;305(5690):1629-31 PMID: 15308764
  30. Tuberculosis - metabolism and respiration in the absence of growth.
    Nat Rev Microbiol. 2005 Jan;3(1):70-80 PMID: 15608701
  31. Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.
    Antimicrob Agents Chemother. 1990 Oct;34(10):1938-43 PMID: 1963289
  32. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy.
    J Exp Med. 1956 Nov 1;104(5):737-62 PMID: 13367341
  33. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.
    Am J Med. 1985 Jun 28;78(6B):116-27 PMID: 3893113
  34. Basic mechanisms of chemotherapy.
    Chest. 1979 Dec;76(6 Suppl):771-81 PMID: 92392
  35. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
    Am Rev Respir Dis. 1989 Apr;139(4):871-6 PMID: 2648911
  36. Prokaryotic toxin-antitoxin stress response loci.
    Nat Rev Microbiol. 2005 May;3(5):371-82 PMID: 15864262
  37. Microbial persistence.
    Yale J Biol Med. 1958 Feb;30(4):257-91 PMID: 13531168
  38. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice.
    Am J Med. 1952 Oct;13(4):389-99 PMID: 12985596
  39. Drug tolerance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1999 Nov;43(11):2600-6 PMID: 10543735
  40. Mechanisms of antibiotic resistance in bacterial biofilms.
    Int J Med Microbiol. 2002 Jul;292(2):107-13 PMID: 12195733
  41. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials.
    J Bacteriol. 2001 Dec;183(23):6746-51 PMID: 11698361
  42. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):700-6 PMID: 1901199
  43. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.
    Appl Microbiol. 1970 Nov;20(5):810-4 PMID: 4991927
  44. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 1973 Aug;4(2):94-104 PMID: 4208508
  45. Exogenous reinfection in tuberculosis.
    Lancet Infect Dis. 2005 Oct;5(10):629-36 PMID: 16183517
  46. Persister cells, dormancy and infectious disease.
    Nat Rev Microbiol. 2007 Jan;5(1):48-56 PMID: 17143318
  47. Isoniazid resistance of exponentially growing Mycobacterium smegmatis biofilm culture.
    FEMS Microbiol Lett. 2003 Oct 24;227(2):171-4 PMID: 14592705
  48. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.
    Bull World Health Organ. 1982;60(4):555-64 PMID: 6754120
  49. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection.
    Am J Med Sci. 1956 Jul;232(1):30-7; passim PMID: 13326887
  50. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.
    Clin Microbiol Rev. 2006 Jul;19(3):558-70 PMID: 16847086
  51. The time-table of tuberculosis.
    Tubercle. 1948 Nov;29(11):245-51 PMID: 18101320
  52. The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    Am Rev Respir Dis. 1980 Jun;121(6):939-49 PMID: 6774638
  53. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis. 1986 May;133(5):779-83 PMID: 2871788
  54. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.
    Antimicrob Agents Chemother. 1990 Jun;34(6):1227-31 PMID: 2393284
  55. M. tuberculosis persistence, latency, and drug tolerance.
    Tuberculosis (Edinb). 2004;84(1-2):29-44 PMID: 14670344
  56. Antibiotic persistence: the role of spontaneous DNA repair response.
    Microb Drug Resist. 2001 Winter;7(4):335-42 PMID: 11822773
  57. Tuberculosis: latency and reactivation.
    Infect Immun. 2001 Jul;69(7):4195-201 PMID: 11401954
  58. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
    Antimicrob Agents Chemother. 2004 Dec;48(12):4907-10 PMID: 15561879
  59. Modelling protection from antimicrobial agents in biofilms through the formation of persister cells.
    Microbiology. 2005 Jan;151(Pt 1):75-80 PMID: 15632427
  60. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.
    Am Rev Respir Dis. 1992 May;145(5):1223-5 PMID: 1586071
  61. Mechanisms of latency in Mycobacterium tuberculosis.
    Trends Microbiol. 1998 Mar;6(3):107-12 PMID: 9582936
  62. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
    Lancet. 2006 Nov 4;368(9547):1575-80 PMID: 17084757
  63. Cord-forming property, lethality and pathogenicity of Mycobacteria.
    Dis Chest. 1956 Dec;30(6):642-8 PMID: 13375458
  64. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.
    J Exp Med. 2003 Sep 1;198(5):705-13 PMID: 12953092
  65. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
    Int J Tuberc Lung Dis. 2006 Mar;10(3):317-22 PMID: 16562713
  66. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis. 1987 Dec;136(6):1339-42 PMID: 2891333
  67. Non-inherited antibiotic resistance.
    Nat Rev Microbiol. 2006 Jul;4(7):556-62 PMID: 16778840
  68. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.
    Ann Intern Med. 1982 Oct;97(4):496-503 PMID: 6751182
  69. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users.
    Ann Intern Med. 1994 Dec 1;121(11):873-6 PMID: 7978701
  70. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis. 1988 May;137(5):1147-50 PMID: 2904237
  71. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.
    Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5 PMID: 15831840
  72. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
    Science. 2005 Jan 14;307(5707):223-7 PMID: 15591164
  73. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
    Lancet. 2002 Aug 17;360(9332):528-34 PMID: 12241657
  74. Prospects for advancing tuberculosis control efforts through novel therapies.
    PLoS Med. 2006 Aug;3(8):e273 PMID: 16866578
  75. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations.
    Antimicrob Agents Chemother. 2005 Apr;49(4):1483-94 PMID: 15793130
  76. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.
    Infect Immun. 2005 Jan;73(1):546-51 PMID: 15618194
  77. Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis.
    Mol Microbiol. 2003 Nov;50(4):1199-213 PMID: 14622409
  78. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months.
    Am Rev Respir Dis. 1984 Jul;130(1):23-8 PMID: 6377997
  79. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity.
    Infect Immun. 2003 Dec;71(12):7099-108 PMID: 14638800
  80. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria.
    Drugs R D. 2006;7(3):133-51 PMID: 16752940
  81. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.
    MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):301-5 PMID: 16557213
  82. The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells.
    Cell Microbiol. 2006 May;8(5):806-14 PMID: 16611229
  83. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Am Rev Respir Dis. 1986 Mar;133(3):423-30 PMID: 2420242
  84. Intraphagocytic growth induces an antibiotic-resistant phenotype of Legionella pneumophila.
    Antimicrob Agents Chemother. 1995 Dec;39(12):2684-8 PMID: 8593002
  85. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis.
    Nat Immunol. 2003 Oct;4(10):949-55 PMID: 14515128
  86. Microbial phenotypic heterogeneity and antibiotic tolerance.
    Curr Opin Microbiol. 2007 Feb;10(1):30-8 PMID: 17215163
  87. Toxin-antitoxin modules as bacterial metabolic stress managers.
    Trends Biochem Sci. 2005 Dec;30(12):672-9 PMID: 16257530
  88. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
    Antimicrob Agents Chemother. 1996 Mar;40(3):799-801 PMID: 8851617
  89. Characterization of mRNA interferases from Mycobacterium tuberculosis.
    J Biol Chem. 2006 Jul 7;281(27):18638-43 PMID: 16611633
  90. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy.
    Am Rev Respir Dis. 1989 Apr;139(4):867-70 PMID: 2930066
  91. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli.
    J Bacteriol. 2004 Dec;186(24):8172-80 PMID: 15576765
  92. The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum.
    J Exp Med. 1949 Dec;90(6):595-607 PMID: 15394076
  93. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance.
    PLoS Med. 2006 Oct;3(10):e384 PMID: 17020405
Article Info
Journal
PLoS medicine
Abbr.
PLoS Med
ISSN
1549-1676
DOI
10.1371/journal.pmed.0040120
Published
2007-03-00
Pages
e120
Language
English
Region
United States
NLM ID
101231360
PMCID
PMC1831743
Subset
IM
Grants
NIAID NIH HHS · R01 AI036396 · United States
External Links
PubMed source DOI: 10.1371/journal.pmed.0040120 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2